Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment. Take 2 mins to learn more.


SpyBiotech was spun out of the University of Oxford’s Jenner Institute and Department of Biochemistry in 2017 to develop an innovative ‘plug and display’ platform technology for the rapid development of vaccines.

The Company currently has three programmes in development: a vaccine for COVID-19 partnered with the Serum Institute of India (SII), Human Cytomegalovirus (HCMV) and Respiratory Syncytial Virus (RSV). SpyBiotech’s antigen presentation platform technology generates a strong neutralising antibody response. Combined with its safety and stability, this enables the rapid development of vaccines for unserved markets, particularly where cold chain logistics present a high barrier to entry.

Founder & CEO

Dr Sumi Biswas

Sumi is a highly qualified immunologist with a compelling vision to apply SpyBiotech’s protein superglue technology to commercial vaccine development and production. She leads on both the scientific and strategic business development of the company.

Sumi combines a deep understanding of the relevant science with an interest in business and a talent for mobilising teams around an inspiring purpose – qualities that were instrumental in securing the company’s initial investment. In 2017, she was named as a rising star in BioBeat’s Movers and Shakers list of 50 inspirational women in the BioTech industry.

Sumi moved to the UK in 2005 having studied microbiology at the University of Bangalore. She rose to become an Associate Professor of Vaccinology at the Jenner Institute, Oxford University’s world-leading vaccines innovation centre, where two of the malaria vaccine candidates against malaria developed by her investigatory team are currently being taken into human clinical trials.

Partner with us?

Get in touch